<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01119677</url>
  </required_header>
  <id_info>
    <org_study_id>108HV103</org_study_id>
    <nct_id>NCT01119677</nct_id>
  </id_info>
  <brief_title>A Study of Avonex to Determine the Effects of Dose Titration on the Incidence of Flu Like Symptoms in Healthy Volunteers</brief_title>
  <official_title>A Randomized, Three-Arm, Dose-Blinded, Parallel-Group Study to Determine the Effect of AvonexÂ® Dose Titration on the Severity and Incidence of Interferon Beta-1a-Related Flu Like Symptoms in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biogen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to determine whether titration of Avonex reduces the&#xD;
      severity of flu-like symptoms (FLS). Secondary objectives of this study are to determine&#xD;
      whether titration of Avonex reduces the incidence of FLS and to evaluate the overall safety&#xD;
      and tolerability of Avonex intramuscular (IM) injections.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 5, 2010</start_date>
  <completion_date type="Actual">October 23, 2010</completion_date>
  <primary_completion_date type="Actual">October 23, 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine whether titration of Avonex reduces the incidence of flu like symptoms</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the overall safety and tolerability of Avonex IM injections</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>No dose titration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fast dose titration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Slow dose titration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avonex</intervention_name>
    <description>Group 1 subjects will receive weekly Avonex 30 mcg (full dose) IM injections from Week 1 to Week 8. Group 2 subjects will titrate in quarter dose increments every week up to a full dose of Avonex over a 3 week period from Week 1 to Week 3 and then continue on full dose from Week 4 to Week 8. Group 3 subjects will titrate in quarter dose increments every 2 weeks up to a full dose of Avonex over a 6 week period from Week 1 to Week 6 and continue on full dose from Week 7 to Week 8</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Must have a Body Mass Index of 19 to 30 kg/m2, and a minimum body weight of 50.0 kg at&#xD;
             Screening.&#xD;
&#xD;
          -  Female participants of childbearing potential must practice effective contraception&#xD;
             during the study and be willing and able to continue contraception for 30 days after&#xD;
             their last dose of study treatment.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Known history of or positive test result for human immunodeficiency virus (HIV),&#xD;
             hepatitis C virus (test for hepatitis C virus antibody [HCV Ab]) or hepatitis B virus&#xD;
             (test for hepatitis B surface antigen [HBsAg] and hepatitis B core antibody [HBcAb])&#xD;
&#xD;
          -  Known history of chronic fatigue syndrome or fibromyalgia&#xD;
&#xD;
          -  Within one month, flu-like illnesses (e.g., gastroenteritis, upper respiratory&#xD;
             infection, common cold)&#xD;
&#xD;
          -  History of severe allergic reactions to any drug or anaphylactic reactions&#xD;
&#xD;
          -  Known allergy to Avonex or any of its components&#xD;
&#xD;
          -  Serious infection (e.g., pneumonia, septicemia) within the 3 months prior to Screening&#xD;
             or active bacterial or viral infection&#xD;
&#xD;
          -  History of alcohol or substance abuse (as defined by the Investigator)&#xD;
&#xD;
          -  Female participants who are pregnant or currently breastfeeding&#xD;
&#xD;
          -  Any previous treatment with any interferon product.10. Vaccinations within 2 weeks or&#xD;
             5 half-lives, whichever is longer, prior to Day 1&#xD;
&#xD;
          -  Blood donation within 30 days prior to Screening&#xD;
&#xD;
          -  Use of any tobacco product more than 5 times within 30 days prior to Screening&#xD;
&#xD;
        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Biogen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <study_first_submitted>May 6, 2010</study_first_submitted>
  <study_first_submitted_qc>May 6, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2010</study_first_posted>
  <last_update_submitted>November 15, 2017</last_update_submitted>
  <last_update_submitted_qc>November 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferon beta-1a</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

